Low sweat secretion due to topiramate;Hiposudación por topiramato

Atencion Primaria

Volumn 30, Issue 4, 2002, Pages 257-258

  Sanchez Calso A ^a   Anton Sanz M C ^a  

^a Medicina de familia   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; CARBAMAZEPINE; PHENYTOIN; RHEUMATOID FACTOR; TOPIRAMATE;

AGITATION; AMNESIA; ANOREXIA; APHASIA; ARTICLE; ATAXIA; CARDIOVASCULAR DISEASE; CASE REPORT; CHILD; CLINICAL FEATURE; COGNITIVE DEFECT; CONFUSION; DEPRESSION; DIPLOPIA; DOSE RESPONSE; DRUG TOLERABILITY; EPILEPSY; FATIGUE; HUMAN; LANGUAGE DISABILITY; MALE; METABOLIC DISORDER; NAUSEA; NYSTAGMUS; PARESTHESIA; SIDE EFFECT; SOMNOLENCE; SWEATING; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE;

EID: 18544395793     PISSN: 02126567     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0212-6567(02)79019-7     Document Type: Article

References (6)

1. a parte). Información Terapéutica del Sistema Nacional de Salud 1999;23:7-26.
2. Mateos Beato F. Nuevas perspectivas en el tratamiento farmacológico de la epilepsia. Información Terapéutica del Sistema Nacional de Salud 1999;23:104-10.
3. Faught E, Wildewr BJ, Ramsay RE, Reife RA, Kramer RD, Pledger G, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200, 400, and 600 mg daily dosages. Neurology 1996;46:1684-90.
4. Pellock JM. Managing pediatric epilepsy syndromes with new antiepileptic drugs. Pediatrics 1999;104:1106-16.
5. Topiramate for epilepsy. The Medical Letter 1997;39:51-2.
6. a ed. Barcelona: Harcourt Brace, 1999; p. 338-41.